Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewing's Sarcoma and Prostate Carcinoma

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Camões, Maria J ^a   Paulo, Paula ^a   Ribeiro, Franclim R ^a   Barros Silva, João D ^a   Almeida, Mafalda ^a   Costa, Vera L ^a   Cerveira, Nuno ^a   Skotheim, Rolf I ^b,c   Lothe, Ragnhild A ^b,c   Henrique, Rui ^a,d   Jerónimo, Carmen ^a,d   Teixeira, Manuel R ^a,c,d  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; SOMATOMEDIN BINDING PROTEIN 3; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR ETS; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ARTICLE; CAV1 GENE; CONTROLLED STUDY; DOWN REGULATION; ECRG4 GENE; EWING SARCOMA; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE UNDEREXPRESSION; HIST1H4L GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGFBP3 GENE; KCNN2 GENE; LDOC1 GENE; MAJOR CLINICAL STUDY; MALE; NROB1 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN BINDING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; TGFBR2 GENE; TISSUE MICROARRAY;

CAVEOLIN 1; CELL LINE, TUMOR; DAX-1 ORPHAN NUCLEAR RECEPTOR; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MICROARRAY ANALYSIS; ONCOGENE PROTEINS, FUSION; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEIN C-FLI-1; PROTO-ONCOGENE PROTEINS C-ETS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SARCOMA, EWING; TRANS-ACTIVATORS;

EID: 84869748097     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049819     Document Type: Article

References (55)

1. Nunn MF, Seeburg PH, Moscovici C, Duesberg PH, (1983) Tripartite structure of the avian erythroblastosis virus E26 transforming gene. Nature 306: 391-395.
2. Seth A, Watson DK, (2005) ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 41: 2462-2478.
3. Sementchenko VI, Watson DK, (2000) Ets target genes: past, present and future. Oncogene 19: 6533-6548.
4. Oikawa T, Yamada T, (2003) Molecular biology of the Ets family of transcription factors. Gene 303: 11-34.
5. Graves BJ, Petersen JM, (1998) Specificity within the ets family of transcription factors. Adv Cancer Res 75: 1-55.
6. Sharrocks AD, (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827-837.
7. Riggi N, Stamenkovic I, (2007) The biology of Ewing sarcoma. Cancer Lett 254: 1-10.
8. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
9. Cerveira N, Ribeiro FR, Peixoto A, Costa V, Henrique R, et al. (2006) TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia 8: 826-832.
10. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 20: 538-544.
11. Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337-8341.
12. Clark JP, Cooper CS, (2009) ETS gene fusions in prostate cancer. Nat Rev Urol 6: 429-439.
13. Paulo P, Barros-Silva JD, Ribeiro FR, Ramalho-Carvalho J, Jeronimo C, et al. (2012) FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer 51: 240-249.
14. Pflueger D, Rickman DS, Sboner A, Perner S, LaFargue CJ, et al. (2009) N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 11: 804-811.
15. Chansky HA, Barahmand-Pour F, Mei Q, Kahn-Farooqi W, Zielinska-Kwiatkowska A, et al. (2004) Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro. J Orthop Res 22: 910-917.
16. Prieur A, Tirode F, Cohen P, Delattre O, (2004) EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol 24: 7275-7283.
17. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, et al. (2007) Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448: 595-599.
18. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, et al. (2008) A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 68: 7629-7637.
19. Gangwal K, Lessnick SL, (2008) Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure. Cell Cycle 7: 3127-3132.
20. Gangwal K, Sankar S, Hollenhorst PC, Kinsey M, Haroldsen SC, et al. (2008) Microsatellites as EWS/FLI response elements in Ewing's sarcoma. Proc Natl Acad Sci U S A 105: 10149-10154.
21. Iljin K, Wolf M, Edgren H, Gupta S, Kilpinen S, et al. (2006) TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 66: 10242-10246.
22. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 10: 177-188.
23. Hollenhorst PC, McIntosh LP, Graves BJ, (2011) Genomic and biochemical insights into the specificity of ETS transcription factors. Annu Rev Biochem 80: 437-471.
24. Laudet V, Hanni C, Stehelin D, Duterque-Coquillaud M, (1999) Molecular phylogeny of the ETS gene family. Oncogene 18: 1351-1359.
25. Ribeiro FR, Paulo P, Costa VL, Barros-Silva JD, Ramalho-Carvalho J, et al. (2011) Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. PLoS ONE 6: e22317.
26. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, et al. (2006) Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res 66: 9937-9947.
27. Mendiola M, Carrillo J, Garcia E, Lalli E, Hernandez T, et al. (2006) The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors. Int J Cancer 118: 1381-1389.
28. Hahm KB, Cho K, Lee C, Im YH, Chang J, et al. (1999) Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. Nat Genet 23: 222-227.
29. Meier VS, Kuhne T, Jundt G, Gudat F, (1998) Molecular diagnosis of Ewing tumors: improved detection of EWS-FLI-1 and EWS-ERG chimeric transcripts and rapid determination of exon combinations. Diagn Mol Pathol 7: 29-35.
30. Anderson J, Gordon A, Pritchard-Jones K, Shipley J, (1999) Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer 26: 275-285.
31. Cerveira N, Torres L, Ribeiro FR, Henrique R, Pinto A, et al. (2005) Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. Cancer Genet Cytogenet 163: 138-143.
32. Pearson H, Stirling D, (2003) DNA extraction from tissue. Methods Mol Biol 226: 33-34.
33. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, et al. (2012) Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 14: 600-611.
34. Schmittgen TD, Livak KJ, (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
35. Takai D, Jones PA, (2002) Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 99: 3740-3745.
36. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T, (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97: 64-71.
37. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, et al. (2003) Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 63: 3735-3742.
38. Ibanez de Caceres I, Cortes-Sempere M, Moratilla C, Machado-Pinilla R, Rodriguez-Fanjul V, et al. (2010) IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29: 1681-1690.
39. Barros R, da Costa LT, Pinto-de-Sousa J, Duluc I, Freund JN, et al. (2011) CDX2 autoregulation in human intestinal metaplasia of the stomach: impact on the stability of the phenotype. Gut 60: 290-298.
40. Sandelin A, Wasserman WW, Lenhard B, (2004) ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res 32: W249-252.
41. Wei GH, Badis G, Berger MF, Kivioja T, Palin K, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29: 2147-2160.
42. Massie CE, Mills IG, (2011) Global identification of androgen response elements. Methods Mol Biol 776: 255-273.
43. Li LW, Yu XY, Yang Y, Zhang CP, Guo LP, et al. (2009) Expression of esophageal cancer related gene 4 (ECRG4), a novel tumor suppressor gene, in esophageal cancer and its inhibitory effect on the tumor growth in vitro and in vivo. Int J Cancer 125: 1505-1513.
44. Nagasaki K, Schem C, von Kaisenberg C, Biallek M, Rosel F, et al. (2003) Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis. Int J Cancer 105: 454-458.
45. Janknecht R, (2005) EWS-ETS oncoproteins: the linchpins of Ewing tumors. Gene 363: 1-14.
46. Mao X, Miesfeldt S, Yang H, Leiden JM, Thompson CB, (1994) The FLI-1 and chimeric EWS-FLI-1 oncoproteins display similar DNA binding specificities. J Biol Chem 269: 18216-18222.
47. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, et al. (1993) The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol 13: 7393-7398.
48. Patel M, Simon JM, Iglesia MD, Wu SB, McFadden AW, et al. (2012) Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription. Genome Res 22: 259-270.
49. Cui J, Rohr LR, Swanson G, Speights VO, Maxwell T, et al. (2001) Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate 46: 249-256.
50. Guo Y, Jacobs SC, Kyprianou N, (1997) Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer 71: 573-579.
51. Williams RH, Stapleton AM, Yang G, Truong LD, Rogers E, et al. (1996) Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 2: 635-640.
52. Danielpour D, (2005) Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur J Cancer 41: 846-857.
53. Nakamura Y, Suzuki T, Arai Y, Sasano H, (2009) Nuclear receptor DAX1 in human prostate cancer: a novel independent biological modulator. Endocr J 56: 39-44.
54. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, et al. (2009) Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 27: 549-560.
55. Szatanik M, Vibert N, Vassias I, Guenet JL, Eugene D, et al. (2008) Behavioral effects of a deletion in Kcnn2, the gene encoding the SK2 subunit of small-conductance Ca2+-activated K+ channels. Neurogenetics 9: 237-248.